Dr. Stephen Hauser was a young resident at Harvard when he met his first patient with multiple sclerosis, a woman with a thriving professional life who’d been completely wiped out by her condition, ...

Early treatment with Ocrevus may help protect the cerebellum from damage in people with multiple sclerosis, a study found.

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Neurology experts from UCSF Health presented new clinical research findings and cutting-edge treatment strategies and received distinguished awards recognition at the American Academy of Neurology’s ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous system, slows disability progression in adults ...

WEDNESDAY, April 9, 2025 (HealthDay News) — Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous system ...

Robert J. Fox, M.D., from the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, and colleagues conducted a phase 3, double-blind, event-driven trial involving 1,131 adults (age range ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

“[Ocrelizumab] is the first and only B-cell therapy approved for RMS and PPMS [primary progressive MS] and after more than ten years of treatment, the majority of people with RMS remain free ...

Michael's, a site of Unity Health Toronto health care network, to learn more about this research, what it means for people with progressive ... MS, and found that Tolebrutinib didn't meet its ...